23:30 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis In vitro and mouse studies identified a hydroxamic acid-based ENPP2 inhibitor that could help treat pulmonary fibrosis. Chemical synthesis and in vitro testing in enzymatic activity assays of hydroxamic acid analogs yielded a...
05:19 , Jun 16, 2017 |  BC Week In Review  |  Company News

LegoChem grants Bridge Biotherapeutics rights to autotaxin candidate

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said it received exclusive, worldwide rights to a small molecule inhibitor of autotaxin (ENPP2; ATX) from LegoChem Biosciences Inc. (KOSDAQ:141080). LegoChem will receive KrW2 billion ($1.8 million) up front...